سعر فاسلودكس 250 مجم / 5 مل 2 حقن مملؤة مسبقاً 2025

Fulvestrant 250 mg/5 ml intramuscular injection in prefilled syringes (AstraZeneca), pack of 2.

• Monotherapy for HR-positive, HER2-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease progression following endocrine therapy.Population: Postmenopausal womenDailyMed (U.S. NLM)
• In combination with ribociclib, palbociclib or abemaciclib for HR-positive, HER2-negative advanced or metastatic breast cancer (initial endocrine-based therapy or after progression on endocrine therapy, per the specific combination).Population: Women (see label for menopausal status per combination)DailyMed (U.S. NLM)

• Most common (>=5%, monotherapy): injection site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, hot flash, vomiting, anorexia, asthenia, cough, dyspnea and constipation; increased hepatic enzymes in more than 15% of patients.International label, same formulation · DailyMed (U.S. NLM)

• Known hypersensitivity to fulvestrant or any of its components.International label, same formulation · DailyMed (U.S. NLM)

• Use with caution in patients with bleeding diatheses, thrombocytopenia or on anticoagulants (intramuscular injection); injection-site events including sciatica and neuropathic pain - take care near the sciatic nerve; can cause fetal harm; may falsely elevate estradiol immunoassay results.International label, same formulation · DailyMed (U.S. NLM)

• Other drugs (general)No known drug-drug interactions are listed in the label.DailyMed (U.S. NLM)

• Can cause fetal harm; verify pregnancy status within 7 days before starting, and advise females of reproductive potential to use effective contraception during treatment and for 1 year after the last dose.International label, same formulation · DailyMed (U.S. NLM)
• Advise not to breastfeed during treatment and for 1 year after the last dose.International label, same formulation · DailyMed (U.S. NLM)

• Fulvestrant: Competitively binds the estrogen receptor and downregulates ER protein (US label).